cerebral small vessel disease
Conditions
Interventions
Experimental group:Ginkgo bilobalide + Lipoic acid + Coenzyme Q + Mecobalt + Idibenone
Sponsors
The Third Affiliated Hospital, Sun Yat-Sen University
Eligibility
Sex/Gender
All
Age
60 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 60-80 years. 2. The presence of at least one of the following vascular risk factors for atherosclerosis: smoking (10 cigarettes per day, smoking age >= 10 years), BMI > 28, hypertension, diabetes, impaired fasting blood glucose or abnormal glucose tolerance, hyperlipidemia, hyperhomocysteinemia, coronary heart disease, symptomatic stroke, and obstructive sleep apnea hypopnea syndrome (OSAHS). 3. The presence of at least one of the following common chronic neurological clinical symptoms of cerebral small vessel disease: cognitive decline, gait or postural balance disorders, vascular parkinsonism, mental or emotional disorders (anxiety, depression, etc.), sleep disorders, urinary and fecal sphincter dysfunction; at least one month after acute lacunar syndrome (pure motor hemiparesis, pure sensory stroke, ataxia hemiparesis, sensorimotor stroke, dysarthria-clumsy hand syndrome, etc.). 4. Magnetic resonance imaging presence of at least two characteristic imaging markers of CSVD that meet the STRIVE criteria: (1) Necessary conditions: lacunar infarct lesions (number >= 1); (2) Contain at least one of the following imaging markers: white matter hyperintensity (Fazekas >= grade 2), microbleeds (number of deep parts >= 1), enlarged perivascular space (number of basal ganglia >= 10). 5. Subjects or legal guardians signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. More than 50% stenosis of intracranial and extracranial arteries or previous carotid endarterectomy; 2. (very) Likely cardiac stroke suggested by TOAST classification; 3. Cortical infarcts or subcortical infarcts greater than 1.5 cm in diameter on MRI (non-acute phase); white matter hyperintensity caused by other diseases such as multiple sclerosis or leukodystrophy; 4. Mini-Mental State Assessment Scale (MMSE, Appendix 3) score 27; 5. Patients who cannot accept head MRI examination; 6. Patients with known renal impairment (eGFR185/110mmHg); 14. Fasting blood glucose 22.2mmol/L; 15. Past history of drug, alcohol or drug abuse; 16. Patients who are known to be allergic to the test drug; 17. Participated in other clinical trials 3 months before the start of this study; 18. The researcher believes that it is not suitable to participate in this research.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| MRI of Brain;High Density Electroencephalogram;SDS Depression Self-Rating Scale Score;SAS Anxiety Self-Rating Scale Score; | — |
Primary
| Measure | Time frame |
|---|---|
| Montreal Cognitive Assessment Scale Score;Gait Scale Score;Pittsburgh sleep quality index ( PSQI); | — |
Countries
China
Contacts
Public ContactLu Zhengqi
The Third Affiliated Hospital, Sun Yat-Sen University
Outcome results
None listed